---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-25-000072"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T11:11:21.951327+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics stockholders approve reverse stock split and ratify auditor at 2025 annual meeting

## Summary
- 66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.
- Ratified CohnReznick LLP as auditor for FY2025 with 66,649,293 votes for, 20,039 against.
- Approved reverse stock split at ratio from 1:5 to 1:50, as determined by Board; 65,141,783 for, 1,540,542 against.
- No broker non-votes reported; both proposals were routine matters.

## SEC filing metadata
- accession: 0001842952-25-000072
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000072/0001842952-25-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295225000072/cntx-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-25-000072
- JSON: https://secwatch.observer/filing/0001842952-25-000072.json
- Plain text: https://secwatch.observer/filing/0001842952-25-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.